All In Biotech

Drug Trial Radar · NCT06368440

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

A Single-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Doses in Japanese and Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

May 15, 2024

Primary completion

Dec 23, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

Conditions

  • Healthy Participants

Interventions

  • AZD6793Drug

    Participants will receive AZD6793 single dose as oral suspension.

  • AZD6793Drug

    Participants will receive AZD6793 multiple doses daily as oral suspension.

  • PlaceboDrug

    Participants will receive matching doses of placebo as oral suspension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (SAD): Number of Participants with Adverse EventsTime frame: From Day 1 up to Follow up visit (Day 7±1)
  2. Part 2 (MAD): Number of Participants with Adverse EventsTime frame: From Day 1 up to Follow up visit (Day 14±1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.